Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.67 |
| ▸ | OGG1 | O15527 | 1/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.64 |
| ▸ | BCKDK | O14874 | 2/20 | 0.64 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.60 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 6/20 | 0.58 |
| ▸ | RAB9A | P51151 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29911721 | 1.00 | MCL1 (1.00) | MCL1HDAC1HDAC8HDAC6OGG1 | |
| Hydrochloric Acid SCHEMBL4950639 | 0.98 | MCL1 (0.96) | MCL1HDAC1HDAC8HDAC6OGG1 | |
| SCHEMBL7088656 | 0.86 | MCL1 (0.76) | MCL1HDAC1HDAC8HDAC6OGG1 | |
| SCHEMBL12644102 | 0.85 | MCL1 (0.73) | MCL1HDAC1HDAC8HDAC6OGG1 | |
| SCHEMBL64428 | 0.85 | MCL1 (0.73) | MCL1HDAC1HDAC8HDAC6OGG1 | |
| SCHEMBL11177633 | 0.84 | MCL1 (0.72) | MCL1HDAC1HDAC8HDAC6OGG1 | |
| SCHEMBL2610241 | 0.83 | MCL1 (0.71) | MCL1HDAC1HDAC8HDAC6OGG1 | |
| SCHEMBL5418076 | 0.83 | MCL1 (0.71) | MCL1HDAC1HDAC8HDAC6OGG1 | |
| SCHEMBL7675240 | 0.83 | MCL1 (0.71) | MCL1HDAC1HDAC8HDAC6OGG1 | |
| SCHEMBL1886020 | 0.80 | HDAC1 (1.00) | MCL1HDAC1HDAC8HDAC6OGG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 481 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108350034-B | Antimicrobial polymyxin derived compounds | 莫纳什大学 | 2022-03-11 | — | — | CN | claimed |
| CN-112574248-A | Preparation method of di- ((3-chlorobenzothiophene-2-ester group) hexafluorophenoxy) axial substituted silicon phthalocyanine | 福建师范大学 | 2021-03-30 | — | — | CN | claimed |
| CN-106748604-B | Method for synthesizing mono-iodo aromatic hydrocarbon or di-iodo aromatic hydrocarbon based on decarboxylation of aromatic carboxylic acid | 湘潭大学 | 2020-06-05 | — | — | CN | claimed |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-03-07 | — | — | US | claimed |
| CN-106432179-A | Preparation method of 4-chloro-1-benzothiophene-2-carboxylic acid | 江苏兢业制药有限公司 | 2017-02-22 | — | — | CN | claimed |
| US-20160368928-A1 | MELAMPOMAGNOLIDE B DERIVATIVES | BIOVENTURES, LLC | 2016-12-22 | — | — | US | claimed |
| US-9328107-B2 | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | claimed |
| US-20150203508-A1 | MELAMPOMAGNOLIDE B DERIVATIVES | BIOVENTURES, LLC | 2015-07-23 | — | — | US | claimed |
| EP-2018371-B1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2015-03-04 | — | — | EP | claimed |
| US-20140235622-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | claimed |
| EP-1615666-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| EP-1615667-A2 | COMBINATIONS OF AN 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| EP-1615698-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| EP-1501829-A1 | THIADIAZOLES OR OXADIAZOLES AND THEIR USE AS INHIBITORS OF JAK PROTEIN KINASE | Vertex Pharmaceuticals Incorporated (US) | 2005-02-02 | — | — | EP | claimed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089470-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089415-A2 | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004058753-A1 | THIADIAZOLES OR OXADIAZOLES AND THEIR USE AS INHIBITORS OF JAK PROTEIN KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-07-15 | — | — | WO | claimed |
| US-20040038992-A1 | Inhibitors of Jak protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-26 | — | — | US | claimed |
| US-20030216390-A1 | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues | NEUROGEN CORPORATION | 2003-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203508-A1 | MELAMPOMAGNOLIDE B DERIVATIVES | CMBL, MGMT, MMAB | MCL1 28/4885HDAC1 677/4885HDAC8 694/4885 |
| US-20030216390-A1 | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues | MCHR1, MCHR2, MC1R | MCL1 3610/4885HDAC1 1635/4885HDAC8 1673/4885 |
| US-20040038992-A1 | Inhibitors of Jak protein kinase | JAK2, JAK1, JAK3 | MCL1 530/4885HDAC1 1692/4885HDAC8 2222/4885 |
| US-20140235622-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR1A | MCL1 1905/4885HDAC1 2819/4885HDAC8 3319/4885 |
| US-20160368928-A1 | MELAMPOMAGNOLIDE B DERIVATIVES | CMBL, MGMT, MMAB | MCL1 28/4885HDAC1 677/4885HDAC8 694/4885 |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR1A | MCL1 1905/4885HDAC1 2819/4885HDAC8 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.